Kenvue misses quarterly estimates as inflation, tariffs squeeze margins

Reuters

Thu, August 6, 2026 astatine 6:47 AM CDT 1 min read

Aug 6 (Reuters) - Kenvue narrowly missed Wall Street estimates for second-quarter results connected Thursday arsenic inflation, ‌tariffs and currency-related costs squeezed margins.

The consumer-health ‌company, presently successful the midst of a $40 cardinal buyout by Kimberly-Clark, ​expects the woody to adjacent successful the 4th fourth of 2026.

• Kenvue's adjusted gross borderline fell to 60.2% from 60.9% a twelvemonth earlier, arsenic inflation, tariffs and ‌currency-related costs outweighed ⁠some of the benefits from supply-chain savings and higher prices.

• The shaper of Tylenol ⁠painkillers and Neutrogena skincare products posted second-quarter adjusted nett of 31 cents per share, marginally beneath analysts' mean ​estimate of ​32 cents, according to ​data compiled by LSEG.

• ‌Quarterly income roseate 3% to $3.96 billion, but somewhat missed analysts' estimation of $3.97 billion.

• Self Care income roseate 2.2% to $1.59 cardinal connected improved Tylenol show successful the U.S., portion Zyrtec and Pepcid gained marketplace share.

• Skin ‌Health and Beauty income roseate 5.1% ​to $1.11 billion, driven by higher ​sales of hair- ​and face-care products, including OGX and Neutrogena.

• ‌Essential Health sales, which see ​Listerine and ​Band-Aid, accrued 2.3% to $1.25 billion.

• The institution expects astir $250 cardinal successful pre-tax charges successful 2026 from ​a restructuring programme ‌aimed astatine simplifying operations, improving its proviso concatenation ​and lowering costs.

(Reporting by Kunal Das successful ​Bengaluru; Editing by Vijay Kishore)